Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a promising clinical-stage biotechnology company with a potential game-changing product candidate, Neflamapimod, that targets age-related neurologic disorders. At the Alzheimer's Association International Conference, the company presented data on treatment effects and pharmacokinetic/pharmacodynamic relationships that show Neflamapimod's potential to slow disease progression, improve biomarkers, and mitigate brain atrophy in dementia with Lewy bodies (DLB). Despite initial challenges in the Phase 2b trial due to patients with Alzheimer's co-pathology and low plasma concentrations, a pivotal trial is being prepared with FDA alignment and potential partnership in place, and further clinical studies in other indications may drive significant upside for the company's valuation.

Bears say

CervoMed is facing risks in initiating its Phase 3 trial for neflamapimod in a timely manner, as well as generating positive data from this pivotal program for regulatory approval. Additionally, potential market uptake may be slow and there is also a risk of dilution in the future. The company also has a planned clinical trial for the treatment of amyotrophic lateral sclerosis, which is slated to start by the end of this year and may provide a potential growth opportunity.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.